Health
Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).
About this update from Labcorp Holdings Inc.
[{"type":"text","content":"New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"BURLINGTON, N.C., May 28, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of its expanded DPYD Genotyping test to help identify cancer patients who may be at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy. Labcorp now offers genotype testing for all DPYD Tier 1 and Tier 2 variants recommended by the Association for Molecular Pathology (AMP).","length":490,"tagName":"p"},{"type":"image","alt":"Labcorp Logo (PRNewsfoto/Labcorp)","displaySize":"","headline":null,"caption":"Labcorp Logo (PRNewsfoto/Labcorp)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":107,"url":"https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eGbvv5TPrHsEYJVmjXqFCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4OQ--/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549","width":400,"height":107},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7hRur8W4jVqyxkW7SEV0OA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3MQ--/https://media.zenfs.com/en/prnewswire.com/dfb2a169dcf74a375ce32bd7ba958549","width":400,"height":107}},"href":"https://mma.prnewswire.com/media/2044800/Labcorp_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Advances in pharmacogenomics are reshaping cancer care," said Marcia Eisenberg, Ph.D., chief scientific officer at Labcorp. "Our expanded DPYD test identifies patients at risk for severe toxicity before treatment begins, supporting safer, more personalized care. This expansion also strengthens Labcorp's pharmacogenomics and oncology portfolio, complementing the company's hereditary cancer testing, screening, diagnostic and precision oncology offerings to support more personalized cancer care across the patient journey."","length":554,"tagName":"p"},{"type":"text","content":"Addressing a Significant Risk in ChemotherapySome patients experience preventable severe toxicity and death from chemotherapy int...